Continuous Glucose Monitoring for Type 2 Diabetes: How Does It Compare with Type 1 Diabetes?

Diabetes Technology & TherapeuticsVol. 24, No. 3 EditorialContinuous Glucose Monitoring for Type 2 Diabetes: How Does It Compare with Type 1 Diabetes?Roy W. Beck and Richard M. BergenstalRoy W. BeckAddress correspondence to: Roy W. Beck, MD, PhD, JAEB Center for Health Research, 15310 Amberly Drive, #350, Tampa, FL 33647, USA E-mail Address: rbeck@jaeb.orghttps://orcid.org/0000-0002-5194-8446JAEB Center for Health Research, Tampa, Florida, USA.*Both authors contributed equally to this study.Search for more papers by this author and Richard M. BergenstalInternational Diabetes Center, HealthPartners Institute, Minneapolis, Minnesota, USA.*Both authors contributed equally to this study.Search for more papers by this authorPublished Online:14 Mar 2022https://doi.org/10.1089/dia.2021.0374AboutSectionsView articleView Full TextPDF/EPUB Permissions & CitationsPermissionsDownload CitationsTrack CitationsAdd to favorites Back To Publication ShareShare onFacebookTwitterLinked InRedditEmail View articleFiguresReferencesRelatedDetailsCited byThe Optimal Duration of a Run-In Period to Initiate Continuous Glucose Monitoring for a Randomized Trial Dan Raghinaru, Peter Calhoun, Richard M. Bergenstal, and Roy W. Beck25 November 2022 | Diabetes Technology & Therapeutics, Vol. 24, No. 12 Volume 24Issue 3Mar 2022 InformationCopyright 2022, Mary Ann Liebert, Inc., publishersTo cite this article:Roy W. Beck and Richard M. Bergenstal.Continuous Glucose Monitoring for Type 2 Diabetes: How Does It Compare with Type 1 Diabetes?.Diabetes Technology & Therapeutics.Mar 2022.153-156.http://doi.org/10.1089/dia.2021.0374Published in Volume: 24 Issue 3: March 14, 2022Online Ahead of Print:October 13, 2021Online Ahead of Editing: September 27, 2021PDF download